Ken Griffin Amylyx Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.65 - $3.24 $33,495 - $65,772	20,300 Added 29.42%	89,300 $289,000
Q2 2024 Aug 14, 2024	SELL	$1.62 - $2.71 $623,376 - $1.04 Million	-384,800 Reduced 84.8%	69,000 $131,000
Q1 2024 May 15, 2024	BUY	$2.71 - $19.57 $614,086 - $4.43 Million	226,600 Added 99.74%	453,800 $1.29 Million
Q4 2023 Feb 14, 2024	BUY	$12.07 - $18.46 $1.36 Million - $2.08 Million	112,900 Added 98.78%	227,200 $3.34 Million
Q3 2023 Nov 14, 2023	BUY	$18.08 - $23.45 $1.09 Million - $1.41 Million	60,200 Added 111.28%	114,300 $2.09 Million
Q2 2023 Aug 14, 2023	SELL	$20.98 - $31.42 $942,002 - $1.41 Million	-44,900 Reduced 45.35%	54,100 $1.17 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $1.31 Million - $1.94 Million	47,300 Added 91.49%	99,000 $2.9 Million
Q4 2022 Feb 14, 2023	SELL	$29.75 - $39.26 $10.7 Million - $14.1 Million	-360,000 Reduced 87.44%	51,700 $1.91 Million
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $2.77 Million - $4.99 Million	161,400 Added 64.48%	411,700 $11.6 Million

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $237M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.